{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:43:34Z","timestamp":1789850614551,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2003,5,5]],"date-time":"2003-05-05T00:00:00Z","timestamp":1052092800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2003,6]]},"DOI":"10.1038\/nm874","type":"journal-article","created":{"date-parts":[[2003,5,23]],"date-time":"2003-05-23T14:46:29Z","timestamp":1053701189000},"page":"750-755","source":"Crossref","is-referenced-by-count":57,"title":["A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects"],"prefix":"10.1038","volume":"9","author":[{"given":"Wolfram E","family":"Samlowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Cuzzocrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Macarthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damali","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Salvemini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2003,5,5]]},"reference":[{"key":"BFnm874_CR1","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0171-2985(86)80121-8","volume":"172","author":"R Mertelsmann","year":"1986","unstructured":"Mertelsmann, R. & Welte, K. Human interleukin-2 molecular biology, physiology and clinical possibilities. Immunobiology 172, 400\u2013419 (1986).","journal-title":"Immunobiology"},{"key":"BFnm874_CR2","first-page":"467","volume-title":"Fundamental Immunology","author":"A Weiss","year":"1993","unstructured":"Weiss, A. T lymphocyte activation. in Fundamental Immunology (ed. Paul, W.E.) 467\u2013504 (Raven, New York, 1993)."},{"key":"BFnm874_CR3","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.4049\/jimmunol.136.12.4480","volume":"136","author":"LL Lanier","year":"1986","unstructured":"Lanier, L.L. et al. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J. Immunol. 136, 4480\u20134486 (1986).","journal-title":"J. Immunol."},{"key":"BFnm874_CR4","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/0008-8749(85)90280-1","volume":"94","author":"EA Grimm","year":"1985","unstructured":"Grimm, E.A. & Wilson, D.J. The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymphocytes. Cell Immunol. 94, 568\u2013578 (1985).","journal-title":"Cell Immunol."},{"key":"BFnm874_CR5","first-page":"5931","volume":"50","author":"WG Harker","year":"1990","unstructured":"Harker, W.G. et al. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis. Cancer Res. 50, 5931\u20135936 (1990).","journal-title":"Cancer Res."},{"key":"BFnm874_CR6","first-page":"S70","volume":"3","author":"RI Fisher","year":"1997","unstructured":"Fisher, R.I. et al. High-dose aldesleukin in renal cell carcinoma: long term survival update. Cancer J. 3, S70\u2013S72 (1997).","journal-title":"Cancer J."},{"key":"BFnm874_CR7","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1200\/JCO.1991.9.4.694","volume":"9","author":"JP Siegel","year":"1991","unstructured":"Siegel, J.P. & Puri, R.K. Interleukin-2 toxicity. J. Clin. Oncol. 9, 694\u2013704 (1991).","journal-title":"J. Clin. Oncol."},{"key":"BFnm874_CR8","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1200\/JCO.1989.7.4.486","volume":"7","author":"KA Margolin","year":"1989","unstructured":"Margolin, K.A. et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines. J. Clin. Oncol. 7, 486\u2013498 (1989).","journal-title":"J. Clin. Oncol."},{"key":"BFnm874_CR9","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1378\/chest.94.4.750","volume":"94","author":"FP Ognibene","year":"1988","unstructured":"Ognibene, F.P. et al. Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest 94, 750\u2013754 (1988).","journal-title":"Chest"},{"key":"BFnm874_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/jnci\/80.3.177","volume":"80","author":"SE Ettinghausen","year":"1988","unstructured":"Ettinghausen, S.E., Puri, R.K. & Rosenberg, S.A. Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J. Natl. Cancer Inst. 80, 177\u2013188 (1988).","journal-title":"J. Natl. Cancer Inst."},{"key":"BFnm874_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1148\/radiology.176.1.2353090","volume":"176","author":"H Mann","year":"1990","unstructured":"Mann, H., Ward, J.H. & Samlowski, W.E. Vascular leak syndrome associated with interleukin-2: chest radiographic manifestations. Radiology 176, 191\u2013194 (1990).","journal-title":"Radiology"},{"key":"BFnm874_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.1989.7.1.7","volume":"7","author":"RE Lee","year":"1989","unstructured":"Lee, R.E. et al. Cardiorespiratory effects of immunotherapy with interleukin-2. J. Clin. Oncol. 7, 7\u201320 (1989).","journal-title":"J. Clin. Oncol."},{"key":"BFnm874_CR13","doi-asserted-by":"publisher","first-page":"953","DOI":"10.7326\/0003-4819-109-12-953","volume":"109","author":"ER Gaynor","year":"1988","unstructured":"Gaynor, E.R. et al. The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann. Intern. Med. 109, 953\u2013958 (1988).","journal-title":"Ann. Intern. Med."},{"key":"BFnm874_CR14","doi-asserted-by":"publisher","first-page":"9753","DOI":"10.1073\/pnas.97.17.9753","volume":"97","author":"H Macarthur","year":"2000","unstructured":"Macarthur, H. et al. Inactivation of catecholamines by superoxide gives new insight into the pathogenesis of septic shock. Proc. Natl. Acad. Sci. USA 97, 9753\u20139758 (2000).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm874_CR15","first-page":"633","volume":"14","author":"DG Graham","year":"1978","unstructured":"Graham, D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and quinones. Mol. Pharmacol. 14, 633\u2013643 (1978).","journal-title":"Mol. Pharmacol."},{"key":"BFnm874_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/0891-5849(92)90182-G","volume":"13","author":"A Bindolini","year":"1992","unstructured":"Bindolini, A., Rigobello, M.P. & Delbi, D.J. Biochemical and toxicological properties of the oxidation products of catecholamines. Free Radic. Biol. Med. 13, 391\u2013395 (1992).","journal-title":"Free Radic. Biol. Med."},{"key":"BFnm874_CR17","first-page":"1176","volume":"40","author":"K Suzuki","year":"1990","unstructured":"Suzuki, K. et al. Priming effect of recombinant human interleukin-2 and recombinant human interferon-\u03b3 on human neutrophil superoxide production. Arzneimittelforschung 40, 1176\u20131179 (1990).","journal-title":"Arzneimittelforschung"},{"key":"BFnm874_CR18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/00002371-199404000-00005","volume":"15","author":"R Faggioni","year":"1994","unstructured":"Faggioni, R. et al. Mechanisms of interleukin-2-induced hydrothorax in mice: protective effect of endotoxin tolerance and dexamethasone and possible role of reactive oxygen intermediates. J. Immunother. Emphasis Tumor Immunol. 15, 194\u2013201 (1994).","journal-title":"J. Immunother. Emphasis Tumor Immunol."},{"key":"BFnm874_CR19","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1084\/jem.161.5.1169","volume":"161","author":"SA Rosenberg","year":"1985","unstructured":"Rosenberg, S.A. et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J. Exp. Med. 161, 1169\u20131188 (1985).","journal-title":"J. Exp. Med."},{"key":"BFnm874_CR20","first-page":"2784","volume":"46","author":"SE Ettinghausen","year":"1986","unstructured":"Ettinghausen, S.E. & Rosenberg, S.A. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2. Cancer Res. 46, 2784\u20132792 (1986).","journal-title":"Cancer Res."},{"key":"BFnm874_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/978-3-0348-8241-5_15","volume-title":"Nitric Oxide and Inflammation","author":"WE Samlowski","year":"2001","unstructured":"Samlowski, W.E. Nitric oxide as a mediator of interleukin-2 induced cardiovascular toxicity and antitumor activity. in Nitric Oxide and Inflammation (eds. Salvemini, D., Billiar, T.R. & Vodovotz, Y.) 249\u2013272 (Birkh\u00e4user Publishing, Basel, 2001)."},{"key":"BFnm874_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3109\/00365519709060027","volume":"57","author":"K Hellsstrand","year":"1997","unstructured":"Hellsstrand, K. et al. Histamine in cancer immunotherapy. Scand. J. Clin. Lab. Invest. 57, 193\u2013202 (1997).","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"BFnm874_CR23","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.4049\/jimmunol.155.9.4382","volume":"155","author":"C-Y Yim","year":"1995","unstructured":"Yim, C.-Y. et al. Nitric oxide synthesis contributes to IL-2 induced antitumor responses against intraperitoneal Meth A tumor. J. Immunol. 155, 4382\u20134390 (1995).","journal-title":"J. Immunol."},{"key":"BFnm874_CR24","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1126\/science.286.5438.304","volume":"286","author":"D Salvemini","year":"1999","unstructured":"Salvemini, D. et al. Synzymes: potent non-peptidic agents against superoxide-driven tissue injury. Science 286, 304\u2013306 (1999).","journal-title":"Science"},{"key":"BFnm874_CR25","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1084\/jem.183.5.2361","volume":"183","author":"JC Becker","year":"1996","unstructured":"Becker, J.C. et al. T-cell mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J. Exp. Med. 183, 2361\u20132366 (1996).","journal-title":"J. Exp. Med."},{"key":"BFnm874_CR26","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/ijc.2910400314","volume":"40","author":"MJ Brunda","year":"1987","unstructured":"Brunda, M.J., Bellantoni, D. & Sulich, V. In vivo anti-tumor activity of combinations of interferon-\u03b1 and interleukin-2 in a murine model: Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int. J. Cancer 40, 365\u2013371 (1987).","journal-title":"Int. J. Cancer"},{"key":"BFnm874_CR27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0065-2776(08)60911-6","volume":"74","author":"FM Marincola","year":"2000","unstructured":"Marincola, F.M., Jaffee, E.M., Hicklin, D.J. & Ferrone, S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74, 181\u2013273 (2000).","journal-title":"Adv. Immunol."},{"key":"BFnm874_CR28","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/jlb.55.3.392","volume":"55","author":"K Hellstrand","year":"1994","unstructured":"Hellstrand, K., Asea, A. & Hermodsson, S. Histaminergic regulation of antibody-dependent cellular cytotoxicity of granulocytes, monocytes and natural killer cells. J. Leukocyte Biol. 55, 392\u2013397 (1994).","journal-title":"J. Leukocyte Biol."},{"key":"BFnm874_CR29","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1002\/eji.1830260620","volume":"26","author":"K Kono","year":"1996","unstructured":"Kono, K. et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cells and natural killer cell-mediated cytotoxicity. Eur. J. Immunol. 26, 1308\u20131313 (1996).","journal-title":"Eur. J. Immunol."},{"key":"BFnm874_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1365-3083.1986.tb02069.x","volume":"24","author":"M Dohlsten","year":"1986","unstructured":"Dohlsten, M. et al. Synergistic action of \u03b3-interferon and catalase to reverse the suppressive effects of peritoneal macrophages on concanavalin A-induced lymphocyte proliferation. Scand. J. Immunol. 24, 49\u201358 (1986).","journal-title":"Scand. J. Immunol."},{"key":"BFnm874_CR31","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1365-3083.1987.tb02255.x","volume":"26","author":"O Linden","year":"1987","unstructured":"Linden, O. et al. Catalase and lipopolysaccharide enhanced proliferation in the rat mixed lymphocyte reaction. Scand. J. Immunol. 26, 223\u2013228 (1987).","journal-title":"Scand. J. Immunol."},{"key":"BFnm874_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF03354243","volume":"43","author":"P Uotila","year":"1996","unstructured":"Uotila, P. The role of cyclic AMP and oxygen intermediates in the inhibition of cellular immunity in cancer. Cancer Immunol. Immunother. 43, 1\u20139 (1996).","journal-title":"Cancer Immunol. Immunother."},{"key":"BFnm874_CR33","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1172\/JCI110527","volume":"69","author":"WE Seaman","year":"1982","unstructured":"Seaman, W.E. et al. Suppression of natural killing in vitro by monocytes and polymorphonuclear leukocytes: requirements for reactive metabolites of oxygen. J. Clin. Invest. 69, 876\u2013888 (1982).","journal-title":"J. Clin. Invest."},{"key":"BFnm874_CR34","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1172\/JCI110161","volume":"67","author":"WE Seaman","year":"1981","unstructured":"Seaman, W.E. et al. Natural killing of tumor cells by human peripheral blood cells: Suppression of killing in vitro by tumor-promoting phorbol diesters. J. Clin. Invest. 67, 1324\u20131333 (1981).","journal-title":"J. Clin. Invest."},{"key":"BFnm874_CR35","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1159\/000235169","volume":"92","author":"K Hellstrand","year":"1990","unstructured":"Hellstrand, K. & Hermodsson, S. Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2. Int. Arch. Allergy Appl. Immunol. 92, 379\u2013389 (1990).","journal-title":"Int. Arch. Allergy Appl. Immunol."},{"key":"BFnm874_CR36","doi-asserted-by":"crossref","first-page":"869","DOI":"10.4049\/jimmunol.139.3.869","volume":"139","author":"K Hellstrand","year":"1987","unstructured":"Hellstrand, K. & Hermodsson, S. Role of serotonin in the regulation of human natural killer cell cytotoxicity. J. Immunol. 139, 869\u2013875 (1987).","journal-title":"J. Immunol."},{"key":"BFnm874_CR37","doi-asserted-by":"crossref","first-page":"656","DOI":"10.4049\/jimmunol.137.2.656","volume":"137","author":"K Hellstrand","year":"1986","unstructured":"Hellstrand, K. & Hermodsson, S. Histamine H2-receptor-mediated regulation of human natural killer cell activity. J. Immunol. 137, 656\u2013660 (1986).","journal-title":"J. Immunol."},{"key":"BFnm874_CR38","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1084\/jem.148.1.115","volume":"148","author":"RB Johnson Jr.","year":"1978","unstructured":"Johnson, R.B. Jr., Godzik, C.A. & Cohn, Z.A. Increased superoxide production by immunologically activated and chemically elicited macrophages. J. Exp. Med. 148, 115\u2013127 (1978).","journal-title":"J. Exp. Med."},{"key":"BFnm874_CR39","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1084\/jem.151.1.101","volume":"151","author":"MJ Pabst","year":"1980","unstructured":"Pabst, M.J. & Johnston, R.B. Increased production of superoxide anion by macrophages exposed in vitro to muramyl dipeptide or lipopolysaccharide. J. Exp. Med. 151, 101\u2013114 (1980).","journal-title":"J. Exp. Med."},{"key":"BFnm874_CR40","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1182\/blood.V97.11.3521","volume":"97","author":"N Moulian","year":"2001","unstructured":"Moulian, N. et al. In vivo and in vitro apoptosis of human thymocytes are associated with nitrotyrosine formation. Blood 97, 3521\u20133530 (2001).","journal-title":"Blood"},{"key":"BFnm874_CR41","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4049\/jimmunol.156.1.42","volume":"156","author":"M Hansson","year":"1996","unstructured":"Hansson, M. et al. Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J. Immunol. 156, 42\u201347 (1996).","journal-title":"J. Immunol."},{"key":"BFnm874_CR42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1006\/cimm.1998.1337","volume":"188","author":"J-Y Kwak","year":"1998","unstructured":"Kwak, J.-Y. et al. Receptor-mediated activation of murine peritoneal macrophages by antithrombin III acts as a costimulatory signal for nitric oxide synthesis. Cell Immunol. 188, 33\u201340 (1998).","journal-title":"Cell Immunol."},{"key":"BFnm874_CR43","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/00002371-199510000-00004","volume":"18","author":"WE Samlowski","year":"1995","unstructured":"Samlowski, W.E. et al. Effectiveness and toxicity of protracted nitric oxide synthesis inhibition during IL-2 treatment of mice. J. Immunother. 18, 166\u2013178 (1995).","journal-title":"J. Immunother."},{"key":"BFnm874_CR44","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1097\/00007890-198904000-00020","volume":"47","author":"DK Bishop","year":"1989","unstructured":"Bishop, D.K. & Orosz, C.G. Limiting dilution analysis for alloreactive, TCGF-secretory T cells Two related LDA methods that discriminate between unstimulated precursor T cells and in vivo-alloactivated T cells. Transplantation 47, 671\u2013677 (1989).","journal-title":"Transplantation"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nm874.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm874","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm874.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T22:34:24Z","timestamp":1684449264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5,5]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["BFnm874"],"URL":"https:\/\/doi.org\/10.1038\/nm874","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5,5]]}}}